Abstract
SB-706375 is a selective receptor antagonist of human urotensin-II (hU-II), which can block the aorta contraction induced by hU-II in rats. The effect of SB-706375 on myocardial ischaemia–reperfusion (I/R) injury is unclear. The major objective of this study was to investigate whether SB-706375 has a protective effect on myocardial I/R injury in rats and explore its possible mechanisms. Isolated hearts of Adult Sprague–Dawley were perfused in a Langendorff apparatus, and haemodynamic parameters, lactate dehydrogenase (LDH), creatine phosphokinase-MB (CK-MB), cardiac troponin I (cTnI), RhoA, and the protein expressions of U-II receptor (UTR), receptor-interacting protein 3 (RIP3), Rho-associated coiled-coil-containing protein kinase 1 (ROCK1) and Rho-associated coiled-coil-containing protein kinase 2 (ROCK2) were assessed. We found that SB-706375 (1 × 10−6 and 1 × 10−5 mol/L) significantly inhibited the changes of haemodynamic parameters and reduced LDH and CK-MB activities and also cTnI level in the coronary effluents in the heart subjected to myocardial I/R injury. Further experiments studies showed that SB-706375 obviously prevented myocardial I/R increased RhoA activity and UTR, RIP3, ROCK1, and ROCK2 protein expressions. ROCK inhibition abolished the improving effect of SB-706375 on myocardial I/R-induced haemodynamic change in the isolated perfused rat heart. These findings suggested that SB-706375 provides cardio-protection against I/R injury in isolated rats by blocking UTR-RhoA/ROCK-RIP3 pathway.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ammirati E, Dobrev D (2018) Conventional troponin-I versus high-sensitivity troponin-T: performance and incremental prognostic value in non-ST-elevation acute myocardial infarction patients with negative CK-MB based on a real-world multicenter cohort. Int J Cardiol Heart Vasc 20:38–39. https://doi.org/10.1016/j.ijcha.2018.07.002
Bao W et al (2004) Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 61:548–558. https://doi.org/10.1016/j.cardiores.2003.12.004
Cadete VJ, Sawicka J, Polewicz D, Doroszko A, Wozniak M, Sawicki G (2010) Effect of the Rho kinase inhibitor Y-27632 on the proteome of hearts with ischemia-reperfusion injury. Proteomics 10:4377–4385. https://doi.org/10.1002/pmic.201000393
Cantin C et al (2019) Effect of early normotension with olmesartan on rho-kinase activity in hypertensive patients. Curr Vasc Pharmacol. https://doi.org/10.2174/1570161117666190121103116
Chen ZW, Yang Q, Huang Y, Fan L, Li XW, He GW (2010) Human urotensin II in internal mammary and radial arteries of patients undergoing coronary surgery. Vasc Pharmacol 52:70–76. https://doi.org/10.1016/j.vph.2009.11.003
Ding H, Gao S, Wang L, Wei Y, Zhang M (2019) Overexpression of miR-582-5p inhibits the apoptosis of neuronal cells after cerebral ischemic stroke through regulating PAR-1/Rho/Rho axis. J Stroke Cerebrovasc Dis 28:149–155. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.09.023
Dominguez-Rodriguez A, Diaz I, Rodriguez-Moyano M, Calderon-Sanchez E, Rosado JA, Ordonez A, Smani T (2012) Urotensin-II signaling mechanism in rat coronary artery: role of STIM1 and Orai1-dependent store operated calcium influx in vasoconstriction. Arterioscl Thromb Vasc Biol 32:1325–1332. https://doi.org/10.1161/atvbaha.111.243014
Douglas SA et al (2005) Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br J Pharmacol 145:620–635. https://doi.org/10.1038/sj.bjp.0706229
Forty EJ, Ashton N (2013) The urotensin system is up-regulated in the pre-hypertensive spontaneously hypertensive rat. PLoS One 8:e83317. https://doi.org/10.1371/journal.pone.0083317
Hamid SA, Bower HS, Baxter GF (2007) Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 292:H2598–H2606. https://doi.org/10.1152/ajpheart.01393.2006
He K et al (2014) ROCK-dependent ATP5D modulation contributes to the protection of notoginsenoside NR1 against ischemia-reperfusion-induced myocardial injury. Am J Physiol Heart Circ Physiol 307:H1764–H1776. https://doi.org/10.1152/ajpheart.00259.2014
Jani PP, Narayan H, Ng LL (2013) The differential extraction and immunoluminometric assay of Urotensin II and Urotensin-related peptide in heart failure. Peptides 40:72–76. https://doi.org/10.1016/j.peptides.2012.12.014
Jeddi S, Khalifi S, Ghanbari M, Bageripour F, Ghasemi A (2016) Effects of nitrate intake on myocardial ischemia-reperfusion injury in diabetic rats. Arq Bras Cardiol 107:339–347. https://doi.org/10.5935/abc.20160137
Kamijo H et al (2011) Impaired vascular remodeling in the yolk sac of embryos deficient in ROCK-I and ROCK-II. Genes Cells 16:1012–1021. https://doi.org/10.1111/j.1365-2443.2011.01546.x
Kilic S et al (2014) The effect of thrombus aspiration during primary percutaneous coronary intervention on clinical outcome in daily clinical practice. Thromb Haemost 111:165–171. https://doi.org/10.1160/TH13-05-0433
Lee JH, Park BK, Oh KS, Yi KY, Lim CJ, Seo HW, Lee BH (2016) A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension. Int Immunopharmacol 40:196–202. https://doi.org/10.1016/j.intimp.2016.09.002
Luo SY, Chen S, Qin YD, Chen ZW (2016) Urotensin-receptor antagonist SB-710411 protects rat heart against ischemia-reperfusion injury via RhoA/ROCK pathway. PloS One 11:6094. https://doi.org/10.1371/journal.pone.0146094
Maryanoff BE, Kinney WA (2010) Urotensin-II receptor modulators as potential drugs. J Med Chem 53:2695–2708. https://doi.org/10.1021/jm901294u
Moriwaki K, Chan FK (2013) RIP3: a molecular switch for necrosis and inflammation. Genes Dev 27:1640–1649. https://doi.org/10.1101/gad.223321.113
Mucha E, Hoefle C, Huckelhoven R, Berken A (2010) RIP3 and AtKinesin-13A—a novel interaction linking Rho proteins of plants to microtubules. Eur J Cell Biol 89:906–916. https://doi.org/10.1016/j.ejcb.2010.08.003
Ocaranza MP, Fierro C, Jalil JE, Moya J, Gonzalez L, Molina C, Mancilla C (2018) Rho kinase activation in circulating leukocytes is related to hypertensive myocardial remodeling. Clin Sci (Lond) 132:1837–1853. https://doi.org/10.1042/CS20180312
Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, Bern HA (1980) Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci USA 77:5021–5024
Sahna E, Acet A, Ozer MK, Olmez E (2002) Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. J Pineal Res 33:234–238
Satoh K, Fukumoto Y, Shimokawa H (2011) Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 301:H287–H296. https://doi.org/10.1152/ajpheart.00327.2011
Shi J, Wei L (2013) Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil. J Cardiovasc Pharmacol 62:341–354. https://doi.org/10.1097/FJC.0b013e3182a3718f
Wang K et al (2016) The long noncoding RNA NRF regulates programmed necrosis and myocardial injury during ischemia and reperfusion by targeting miR-873. Cell Death Differ 23:1394–1405. https://doi.org/10.1038/cdd.2016.28
Yang Z et al (2018) Melatonin attenuates chronic pain related myocardial ischemic susceptibility through inhibiting RIP3-MLKL/CaMKII dependent necroptosis. J Mol Cell Cardiol 125:185–194. https://doi.org/10.1016/j.yjmcc.2018.10.018
You Z, Genest J Jr, Barrette PO, Hafiane A, Behm DJ, D’Orleans-Juste P, Schwertani AG (2012) Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequalae in mice. Arterioscl Thromb Vasc Biol 32:1809–1816. https://doi.org/10.1161/atvbaha.112.252973
Yu ZY et al (2014) RhoA/ROCK signaling and pleiotropic alpha1A-adrenergic receptor regulation of cardiac contractility. PloS One 9:e99024. https://doi.org/10.1371/journal.pone.0099024
Zhang JY, Chen ZW, Yao H (2012) Protective effect of urantide against ischemia-reperfusion injury via protein kinase C and phosphtidylinositol 3′-kinase—Akt pathway. Can J Physiol Pharmacol 90:637–645. https://doi.org/10.1139/y2012-048
Zhang T et al (2016) CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med 22:175–182. https://doi.org/10.1038/nm.4017
Zhang FW, Tong J, Yan YS, Chen QQ, Zhao XP (2018a) omega-3 polyunsaturated fatty acid postconditioning protects the isolated perfused rat heart from ischemia-reperfusion injury. Cardiorenal Med 8:173–182. https://doi.org/10.1159/000487490
Zhang X et al (2018b) Clinical significance of increased urotensin II levels in acute myocardial infarction. Discov Med 26:7–20
Zhuang R et al (2018) Fasudil preserves lung endothelial function and reduces pulmonary vascular remodeling in a rat model of endstage pulmonary hypertension with left heart disease. Int J Mol Med 42:1341–1352. https://doi.org/10.3892/ijmm.2018.3728
Acknowledgements
This work was financially supported by the National Natural Science Foundation of China (Project # 81374002, to Z.-W. Chen).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Duan, JS., Chen, S., Sun, XQ. et al. Urotensin-#receptor antagonist SB-706375 protected isolated rat heart from ischaemia–reperfusion injury by attenuating myocardial necrosis via RhoA/ROCK/RIP3 signalling pathway. Inflammopharmacol 27, 1309–1318 (2019). https://doi.org/10.1007/s10787-019-00598-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10787-019-00598-1